Investor Relations

Investor Presentation

View our latest Investor Presentation to find the most recent investor-related information.

View Investor Presentation

Latest News

View All News
Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement
Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement

Latest Presentation

Q2 2025 Investor Presentation
View All Presentations

Latest Financial Results

Q1 2025

Quarter Ended March 31, 2025

10-Q

HTML PDF XBRL Zip

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

View 10-K

Company Information

Pelthos Therapeutics is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens.

ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum is now approved by the U.S. Food and Drug Administration. In addition to ZELSUVMI™, Pelthos has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL™. Complete prescribing information and important safety information is available at www.zelsuvmi.com.

View Executive Team View Board of Directors

IR Contacts

Company

Pelthos Therapeutics Inc.
4020 Stirrup Creek Drive
Suite 110
Durham, NC 27703
United States
T: 1.919.908.2400
contact@pelthos.com

Connect With Us